Jade Biosciences Inc Ordinary Shares JBIO 深 沪
已收盘 09-19 16:00:00 美东时间
7.42
-0.290
-3.76%
华盛通- 最 高7.88
- 今 开7.80
- 成交量 18.96万股
- 最 低 7.38
- 昨 收 7.71
- 总市值 2.42亿
- 52周最高 21.00
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 -19.60
- 委 比 97.54%
- 总股本 3262.67万
- 历史最高 1050.525
- 量 比 2.78
- 振 幅 6.49%
- 历史最低 -40.25
- 每 手 1
- 风险率 6.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jade Biosciences’ Chief Medical Officer Departs
Jade Biosciences ( ($JBIO) ) has provided an announcement. On September 9, 2025...
09-09 19:27
Jade Biosciences Starts Phase 1 Trial Of JADE101 Antibody For IgA Nephropathy, Eyes 2026 Data
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has dosed the first
09-02 19:03
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
A clinical-stage biotechnology company, Jade Biosciences, has initiated a Phase 1 trial for JADE101, a monoclonal antibody targeting APRIL for IgAN treatment. JADE101 shows high binding affinity and potential for infrequent dosing. Mid-2026 interim data will guide dose selection based on biomarkers.
09-02 11:00
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $18
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $17 to $18.
08-14 22:02
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jade Biosciences reported financial results for Q2 2025, highlighting $220.9M in cash and plans to advance its lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy. Preclinical data presented at the European Renal Association Congress demonstrated JADE101's potential as a best-in-class therapy, with strong APRIL binding affinity and sustained IgA suppression. A Phase 1 clinical trial in healthy volunteers is expected to b...
08-13 20:05
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market t...
07-17 18:15
Jade Biosciences to Participate in Two Upcoming Investor Conferences
Jade Biosciences announced its participation in two upcoming investor conferences. CEO Tom Frohlich and CSO Andrew King will discuss the company's pipeline, including JADE101 for immunoglobulin A nephropathy, at the H.C. Wainwright Kidney Virtual Conference on July 14 and the Stifel Biotech Summer Summit on August 13. Both events will include fireside chats and one-on-one investor meetings. Jade is focused on developing best-in-class therapies fo...
07-08 11:00
Jade Biosciences appoints Brad Dahms as CFO
Jade Biosciences (NASDAQ:JBIO) has appointed Brad Dahms as Chief Financial Officer. Mr. Dahms held management positions in various companies inlcuding most recently being Chief Financial Officer and C...
07-01 19:28
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Jade Biosciences, Inc., a biotech company focused on autoimmune diseases, has appointed Brad Dahms as its Chief Financial Officer. Dahms, with a strong track record in biotech finance and strategic leadership, joins Jade to support its growth, including advancing its lead candidate JADE101 for IgA nephropathy into clinical trials in 2025. His prior experience includes roles at IDRx, Theseus Pharmaceuticals, and Selecta Biosciences, where he led f...
07-01 11:00
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
